DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Press releases

Here you can find corporate releases on topics related to governance, investments and important announcements.

Read more

Investors

Nasdaq:

CRMD

$ 4.11 Last update: 03/28/2024 8:35:00 am ET Time Read more

About CRBSI

Learn more about CRBSIs and how they affect CVC-HD patients.

Read more